Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sandler

Showing results (731-740 of 870) with videos related to

Pageof 87
Sort By:
The Journal of Urology|December 17, 2013
Satisfaction with information used to choose prostate cancer treatmentScott M Gilbert, Martin G Sanda, Rodney L Dunn, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233Timur Mitin, Asha George, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, et al.
The New England Journal of Medicine|July 15, 2011
Radiotherapy and short-term androgen deprivation for localized prostate cancerChristopher U Jones, Daniel Hunt, David G McGowan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 TrialsJan C Buckner, Karla V Ballman, John C Michalak, et al.
Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.
Radiology|October 19, 2000
Radiologic investigation of patients with hematuria. American College of Radiology. ACR Appropriateness CriteriaJ H Newhouse, E S Amis, L R Bigongiari, et al.
Radiology|October 19, 2000
Pretreatment staging of invasive transitional cell carcinoma of the bladder. American College of Radiology. ACR Appropriateness CriteriaL R Bigongiari, E S Amis, E I Bluth, et al.
Radiology|October 19, 2000
Renal cell carcinoma staging. American College of Radiology. ACR Appropriateness CriteriaP L Choyke, E S Amis, L R Bigongiari, et al.
Urology|October 22, 2013
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective studyHiram Alberto Gay, Jeff M Michalski, Daniel A Hamstra, et al.
Pageof 87

Showing results (731-740 of 870) with videos related to

Sort By:
Pageof 87
The Journal of Urology|December 17, 2013
Satisfaction with information used to choose prostate cancer treatmentScott M Gilbert, Martin G Sanda, Rodney L Dunn, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233Timur Mitin, Asha George, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, et al.
The New England Journal of Medicine|July 15, 2011
Radiotherapy and short-term androgen deprivation for localized prostate cancerChristopher U Jones, Daniel Hunt, David G McGowan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 TrialsJan C Buckner, Karla V Ballman, John C Michalak, et al.
Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.
Radiology|October 19, 2000
Radiologic investigation of patients with hematuria. American College of Radiology. ACR Appropriateness CriteriaJ H Newhouse, E S Amis, L R Bigongiari, et al.
Radiology|October 19, 2000
Pretreatment staging of invasive transitional cell carcinoma of the bladder. American College of Radiology. ACR Appropriateness CriteriaL R Bigongiari, E S Amis, E I Bluth, et al.
Radiology|October 19, 2000
Renal cell carcinoma staging. American College of Radiology. ACR Appropriateness CriteriaP L Choyke, E S Amis, L R Bigongiari, et al.
Urology|October 22, 2013
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective studyHiram Alberto Gay, Jeff M Michalski, Daniel A Hamstra, et al.
Pageof 87